PhaseBio Pharmaceuticals Non-current Revenue (Deferred)

Non-current Revenue (Deferred) of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-current Revenue (Deferred) growth rates and interactive chart.


Highlights and Quick Summary

  • Non-current Revenue (Deferred) for the quarter ending September 29, 2021 was $7.91 Million (a -3.95% decrease compared to previous quarter)
  • Year-over-year quarterly Non-current Revenue (Deferred) increased by Infinity%
  • Annual Non-current Revenue (Deferred) for 2019 was $0 (a -100.0% decrease from previous year)
  • Annual Non-current Revenue (Deferred) for 2018 was $22 Thousand (a 340.0% increase from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-current Revenue (Deferred) of PhaseBio Pharmaceuticals

Most recent Non-current Revenue (Deferred)of PHAS including historical data for past 10 years.

Interactive Chart of Non-current Revenue (Deferred) of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Non-current Revenue (Deferred) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $7.91 $8.24
2019 $0.0
2018 $0.02 $0.0 $0.0 $0.02
2017 $0.0 $0.01

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.